Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Obesity Treatments Weight Loss Drugs FDA Approval Schizophrenia Treatments Obesity Drugs Combination Therapy CagriSema Gilead Sciences Phase I Trial Phase II Trial Weight Loss Treatments Liver Therapies Obexelimab Weight Loss Medications Regulatory Approval Psychoactive Drugs Zaltenibart Atezolizumab Synthetic Psilocybin Eli Lilly

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Regulators will now evaluate linking immunotherapy use to a ctDNA companion test.

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory